We present a novel, cost efficient two-phase design for predictive clinical gene expression studies: early marker panel determination (EMPD). In Phase-1, genome-wide microarrays are used only for a small number of individual patient samples. From this Phase-1 data a panel of marker genes is derived. In Phase-2, the expression values of these marker panel genes are measured for a large group of patients and a predictive classification model is learned from this data. Phase-2 does not require the use of expensive whole genome microarrays, thus making EMPD a cost efficient alternative for current trials. The expected performance loss of EMPD is compared to designs which use genome-wide microarrays for all patients. We also examine the trade-off between the number of patients included in Phase-1 and the number of marker genes required in Phase-2. By analysis of five published datasets we find that in Phase-1 already 16 patients per group are sufficient to determine a suitable marker panel of 10 genes, and that this early decision compromises the final performance only marginally.
Introduction
Recent publications demonstrated the high potential of gene expression studies using microarrays for the diagnosis of tumor entities (Bhattacharjee et al., 2001; Yeoh et al., 2002) , the determination of risk groups (Huang et al., 2003; van't Veer et al., 2002) , and the prediction of the response to treatment (Cheok et al., 2003) . The challenge to associate expression patterns with clinical disease phenotypes is still active focus of current research. In microarray based clinical studies, tissue samples are characterized by high dimensional vectors, containing the expression levels of thousands of genes. These datasets typically consist of tens or hundreds of samples (patients), but contain several thousand variables (expression levels of genes). This setting, with more variables than samples, leads to saturated models. Additional constraints or regularization techniques are required to derive predictive classification models that generalize well. A widely used regularization approach is variable selection, i.e., constraining classification models to only a few, selected variables. In the context of microarray classification, those variables are marker genes. Several methods for variable selection were proposed by Golub et al. (1999) ; Ben-Dor et al. (2000) ; Dudoit et al. (2002) ; Roth et al. (2002) and compared in Dudoit et al. (2002) ; Jaeger et al. (2003) . On the one hand, variable selection serves the statistical purpose of deriving classification models that generalize well (Tibshirani et al., 2002) . On the other hand, it allows for a cost efficient study design as we will show in this paper. Our main finding is that the sample-size requirements for variable selection are lower than those for classifier learning, i.e., few samples can be used efficiently to determine a set of variables on which a classifier is further fine-tuned using a large number of samples.
Current clinical studies collect whole genome data of all patients screened. Then they apply gene selection to the complete dataset. In this paper we suggest a novel two step approach to which we refer to as Early Marker Panel Determination (EMPD). In the first step (Phase-1), genome-wide microarrays are used to screen a small number of patients only and to derive a diagnostic marker panel from this data. In the second step (Phase-2), the expression values of these marker genes only are measured in a large group of patients. This dataset is used for calibrating the final predictive model. Thus EMPD is less expensive because expression analysis of a small set of genes can be done very cost efficiently using alternative quantification methods like quantitative reverse transcription PCR (qRT-PCR, Heid et al. (1996) ). However, since less data is available for variable selection we will loose predictive performance.
The paper is organized as follows: In section 2 we describe the subsampling based evaluation procedure to determine the expected performance loss caused by EMPD. In section 3 we evaluate the loss of performance by EMPD analyzing five publicly available datasets. We conclude with a summary of our findings and discuss their implications for the design of clinical microarray studies.
2 A subsampling approach to evaluate the effect of EMPD Since published datasets for the two phase design of EMPD are not available, we exploit data from large clinical whole genome studies. We simulate Phase-1 by randomly choosing a subset of n 0 patients for which we use the complete expression profiles determined on whole genome microarrays. From this data we determine the marker panel. To simulate Phase-2 we ignore all non-marker-panel genes. With the expression values of marker panel genes obtained from Phase-1 and Phase-2, we finally determine a classification model. All datasets in this paper can be divided into two groups of patients. More formally, let N be the total number of samples in a dataset, with N/2 samples in each group. Let M be the total number of genes on the microarray used during Phase-1. After having analyzed a subset of n 0 < N patients with n 0 /2 samples in each group, we decide on a small set of genes m 0 M. To account for sample variance effects, we randomly draw 30 sample subsets S i , i ∈ {1, .., 30} of size n 0 without replacement. Analyzing only the patients in S i we derive a virtual marker panel P i containing m 0 genes. Finally, we train a multivariate classification model using the complete set of samples but analyzing only genes from the panel P i . We evaluate the performance of this classifier denoting the prediction accuracies by A i (n 0 , m 0 ) = (N − E i )/N , where E i is the number of misclassifications. In total, this gives us 30 accuracy values A i (n 0 , m 0 ) for each combination of values n 0 and m 0 . We denote A(n 0 , m 0 ) as the median of these 30 values. To estimate the performance of EMPD, we compare A(n 0 , m 0 ) to the leave-one-out estimate A(N − 1, m 0 ), which reflects the performance of the traditional approach including all patients in the analysis. Note, that we cannot unbiasedly compare to N samples. At least one sample has to be left out as a test set.
The evaluation of classifier performance is nontrivial. Several papers have pointed out possible pitfalls leading to over optimistic estimators (Ambroise and McLachlan, 2002; West et al., 2001; Chatfield, 1995) . To avoid the feature selection bias described in Ambroise and McLachlan (2002) , we use external leave-one-out cross validation (LOOCV) where in each step feature selection is performed separately. Iteratively, we set aside each sample as a test sample, then we randomly draw n 0 /2 samples for each group from the remaining samples. On these n 0 samples we determine the m 0 marker panel genes. Using these genes only on N − 1 samples, we train a Support Vector Machine (SVM). This SVM then classifies the left-out sample. After each sample has been left out in turn we obtain N classification results and compare them to the known labels to determine the error rates E i (Fig. 1) .
On randomized class labels, this procedure gives the expected prevalence of 50% (data not shown). To estimate variability, Mukherjee et al. (2003) pointed out that the observed variance of classifier performances is higher than the expected population variance but the quantiles of the leave-one-out estimator are unbiased. We therefore use boxplots showing quantiles in figures 2 and 3. For simplicity, we only apply two standard variable selection procedures. The marker panels P i consist of the m 0 genes with the highest two-sample tstatistic or Wilcoxon rank sum statistic, respectively, in S i . The related problem of how to select markers has been addressed in the literature before. For a comparative study of several feature selection methods and classifiers see Lee et al. (2005) and Jaeger et al. (2003) . Subsequent model fitting is done using SVMs with radial basis function kernels (Gist 1.3βwith default parameters; http://microarray.genomecenter.columbia.edu/gist/). To evaluate EMPD for 10 different choices of m 0 and n 0 , respectively, on one dataset with 128 samples, the procedure needs 24 hours CPU time parallelized on 8 Athlon 1.8GHz machines. 
Applications of EMPD
We examine five published datasets (Tab. 1). All five datasets use Affymetrix HGU95Av2 DNA chips containing 12625 probesets, corresponding to more than 9000 known, unique, human genes. For preprocessing, we perform background correction, normalization on probe level, and probeset summarization. The background correction is done similarly to MAS 5 (Affymetrix, 2001) but negative values are not truncated. Probe level normalization is done using the variance stabilization method by Huber et al. (2002) . Finally, probeset summarization is performed using a median polish fit of an additive model described in Irizarry et al. (2003) . For simplicity, we focus on classification problems with only two possible outcomes and randomly omit samples to obtain balanced sample numbers in each group.
The first dataset is a study on acute lymphocytic leukemia (ALL) in children (Yeoh et al., 2002) . 327 leukemia samples fall into different clinical classes characterized by immunophenotype, chromosomal translocations and aberrations. In this paper we focus on the diagnosis of hyper-diploid B-cell leukemias, a moderately complicated diagnostic problem. Using a balanced subset of all 64 samples displaying hyper-diploidy with more than 50 chromosomes and 64 samples randomly chosen from the rest of the samples, we achieve a LOOCV performance of 96% correct SVM classifications. The second dataset consists of 102 tumor and normal prostate tissues (Singh et al., 2002) . We obtain 92% accuracy for the classification of 50 tumor versus 50 normal tissues. Furthermore, we examine a dataset of lung cancer samples (Bhattacharjee et al., 2001) , where 98% accuracy for the classification of 21 squamous carcinomas versus 21 adenocarcinomas is achieved. The last dataset contributed by Huang et al. (2003) consists of 89 breast cancer samples which are divided into a study for recurrence (34 non-recurrent and 18 recurrent patients, further denoted as breastR) and a study for lymph-node risk (18 high-risk and 19 low risk samples, further denoted as breastL). In this prognosis setting we classify 92% of the samples correctly using SVM on 18 recurrent versus 18 samples randomly chosen from the non-recurrent pool. In the lymph-node risk study, 65% of the samples were classified correctly. The later is a hard classification task, achieving a performance slightly above random guessing.
We describe the results of the first dataset in detail and only summarize corresponding results of the four other datasets in tables 2 and 3. To evaluate EMPD, we first examine
Dataset
Group 1: sample size Group 2: sample size Leukemia (Yeoh et al., 2002) Hyper-diploid: 64 Other B-cells: 64 of 200 Prostate (Singh et al., 2002) Normal: 50 Tumor: 50 of 52 Lung (Bhattacharjee et al., 2001) Squamous: 21 Adenocarcinomas:21 of 190 BreastR (Huang et al., 2003) Recurrent: 18 Non-recurrent: 18 of 34 BreastL (Huang et al., 2003) High risk: 18 Low Risk: 18 of 19 Table 1 Datasets used for the evaluation of EMPD. Groups 1 and 2 denote the groups used for the evaluation with EMPD and their sample sizes. the loss of prediction accuracy for a fixed marker panel size. For a marker panel of 10 genes, less than 20 samples in Phase-1 are sufficient to reach saturating performances (Fig.  2) . Such a small marker panel may readily be examined by qRT-PCR. Without EMPD, we observe a median accuracy of A(N − 1, 10) = 93%. As expected, EMPD reduces the median accuracy and increases its variance. However, except for extremely small sample sizes in Phase-1, the loss in accuracy appears to be marginal. Even with only 12 patients per group we get A(12 * 2, 10) = 89% corresponding to 96% relative accuracy i.e., accuracy in relation to standard classification that uses all data for the feature selection (relative accuracy = A(n 0 , m 0 )/A(N − 1, m 0 )). The use of relative accuracies allows a comparison of the EMPD results of datasets with different final classification power. Note, that these results do not differ notably when using a Wilcoxon or t-statistic. There is a trade-off between the number of patients used in Phase-1 and the size of the marker panel. Larger marker panels can achieve state of the art performance with only a few patients in Phase-1. For a fixed Phase-1 sample size of n 0 = 10 * 2 and varying marker panel sizes m 0 , satisfying results cannot be achieved with panel sizes of 2 and 3 markers (Fig. 3) . However, already 10 genes lead to an absolute accuracy of 88%. With 30 genes the absolute accuracy reaches 92%. Using more genes (m 0 = 100) increases the accuracy to 94% which corresponds to a relative accuracy of 99%. The results suggest that there is a direct sample size -panel size trade-off. Using more marker genes facilitates a Phase-1 with less samples, whereas more samples in Phase-1 permit a smaller marker panel. We have determined the number of genes required to reach a relative accuracy of ≥95% for a Phase-1 with a given number of n 0 samples (Fig. 4) . The corresponding plots for the other 4 studies are similar (data not shown). EMPD can therefore be used to determine the number of necessary marker genes for a given Phase-1 size. Vice versa, it can be used to determine the number of samples needed in Phase-1 for a given marker panel size.
We determined the relative accuracy of EMPD with a marker panel size of m 0 = 10 genes and m 0 = 100 genes. For the small marker panel with m 0 = 10 genes, a very small Phase-1 with 5 patients is enough to achieve ≥92% relative performance for the lung and the leukemia dataset. When doubling Phase-1 to 10 patients per group, already four datasets achieve ≥95% relative accuracy. Only the breastR dataset needs more samples in Phase-1 . Relationship between the number of genes in the marker panel and the number of samples examined in Phase-1 to achieve a relative accuracy of at least 95% (A(n 0 , m 0 )/A(N −1, m 0 )≥95%) in the leukemia dataset (Yeoh et al., 2002) . The dotted line depicts the curve when using a Wilcoxon test statistic, the solid line when using a two sample t-statistic.
and achieves ≥94% relative accuracy with 15 patients in Phase-1 (Table 2 ). When using m 0 = 100 all datasets but the lung dataset achieve relative accuracies ≥99% with only 10 patients per group. The advantage of EMPD is that it can successfully accommodate both, a limited number of genes in the marker panel as well as a limited number of samples to be screened in Phase-1. leukemia 92% 95% 98% 98% 99% 100% prostate 76% 95% 97% 93% 99% 100% lung 95% 99% 100% 93% 95% 98% breastL 85% 100% 100% 100% 100% 100% breastR 73% 86% 94% 90% 100% 100% Table 2 Relative classification accuracy of EMPD (A(n 0 , m 0 )/A (N −1, m 0 ) ). Accuracies are calculated using SVM leave-one-out cross-validation.
We found that the leukemia and the lung data allow good predictive performance with an extremely small Phase-1 even for a marker panel with just 10 genes. For the leukemia dataset, 12 patients, for the breastL dataset 9 patients and for the lung dataset 3 patients are sufficient to achieve ≥95% relative accuracy. For the prostate and breastR cancer dataset, a larger Phase-1 (15 and 16 patients) is needed (Table 3) .
We also investigated the overlap of marker panels across 30 runs of random subsampling. The good performance of EMPD suggests that there are many informative genes and that prediction can be based on very different combinations of them. Especially for small n 0 the leukemia 64  12  2  prostate 50  15  6  lung 21  3  2  breastL 18  9  4  breastR 18  16  10  Table 3 Comparison of sample requirements for EMPD, with a small (m 0 = 10) or a medium size (m 0 = 100) marker panel, to achieve at least 95% relative accuracy. Accuracies are calculated by standard SVM leave-one-out cross-validation. N/2 denotes the total number of samples per group in the datasets. marker panels hardly overlap at all. For harder classification tasks the overlap is in general smaller and increases slower in n 0 (Fig. 5) .
Discussion
We propose a novel, two step study design for clinical gene expression profiling studies. For a small number of patients whole genome microarray data is collected (Phase-1). Then a marker panel is determined from this Phase-1 data. From now on, this marker panel is used to screen a large patient pool (Phase-2). Furthermore, we introduce a novel evaluation procedure to determine the loss in classification accuracy depending on the number of patients in Phase-1 and the size of the marker panel.
Analyzing five published clinical microarray datasets we find that in Phase-1 as little as 16 patients per group are sufficient to identify a panel of 10 marker genes. For a marker panel of 100 genes, not more than 10 patients per group are needed. The early decision on the marker panel compromises the final performance of the diagnostic classification only marginally. We show that there is an inverse relationship between the number of samples in Phase-1 and the size of the marker panel. Using more samples in Phase-1 facilitates the identification of a more reliable set of markers. Therefore, fewer markers are sufficient to achieve the same relative performance. On the other hand, if it is possible to use many markers, only few samples need to be screened in Phase-1.
Our results demonstrate that EMPD is a feasible design for cost efficient clinical studies based on gene expression levels. Material, production and handling costs can be saved. Since only few genes in Phase-2 need to be examined, it is possible to utilize small custom diagnostic mRNA arrays or other technologies like qRT-PCR, in-situ hybridization or protein panels (Büssow et al., 2001) . These technologies may also be closer to the clinical phenotype (protein panel) or more precise (qRT-PCR).
It is important to note that we obtain different marker panels using different subsets of patients for EMPD without a noticeable loss of classification accuracy. Notably, a small sample size of only 10-20 patients may not be enough to determine the most comprehensive set of discriminating genes. However, for a good classification performance it is not necessary to identify those genes. It is not even necessary that all genes in the panel are informative marker genes. In many cases, a few informative genes in the panel are enough to obtain a strong signature at the end of Phase-2. Our observation that finding marker genes for classification is easy and does not require many patients suggests that there are many, probably up to thousands of informative genes in all five studies. In fact, estimating the number of differentially expressed genes using the method by Scheid and Spang (2004) indicates several thousand differentially expressed genes in all four studies, too. However, it is unclear whether the molecular cause of the clinical phenotypes involves several thousand genes. On the other hand, classification does not need to identify causes. Genes involved in secondary and tertiary effects are valuable molecular markers as well. While these marker genes may serve well for diagnostic purposes, they may not be useful to elucidate the molecular basis of a disease and many of them can be replaced by equally well performing marker genes.
While our results show that the relative accuracy after EMPD is only slightly compromised even for problems with a poor overall performance, it is clear that EMPD can not improve absolute performance. If the absolute performance without EMPD is insufficient for practical use, EMPD is of no use too. This paper is purely descriptive, and our findings only apply to the five datasets shown. However, since our results in all five studies are consistent, we believe that EMPD is appropriate for other clinical studies as well and even ongoing studies may benefit. But for a study that has no fixed sample size target N, it is not clear how to determine the optimal length of Phase-1 or the optimal number of marker genes. From this perspective, it would be helpful to have a computational tool to guide EMPD during a running genome-wide study. Our evaluation procedure does not enable us to do this. In an ongoing study, performance at the end of Phase-2 cannot be evaluated, but needs to be extrapolated from the available Phase-1 data. Mukherjee et al. (2003) introduced a method for sample size estimation using powerlaw extrapolation. This approach can be extended to EMPD as well and needs to be further investigated. Genetics and Molecular Biology, Vol. 4 [2005] , Iss. 1, Art. 9 DOI: 10.2202 /1544 -6115.1109 
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